DAd5GNE: Phase I started

Weill Cornell began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate 6 injections of 100, 316 and 1,000 ug dAd5GNE in up to 30 active cocaine addicts. Patients will receive 5 booster...